Moderna’s CEO Stéphane Bancel spoke at the Boston College Chief Executives Club on April 5. While COVID-19 vaccine production was a big talking point for the leader of Moderna, he also touched on how mRNA technology can usher us into a longer life span, saying that he tells all of his friends to “not die” in the next ten years.
New research out of Harvard University strongly suggests that infection with the Epstein-Barr virus (EBV) is the leading cause of a debilitating disease of the brain and CNS – multiple sclerosis.
ESMO: Merck and AstraZeneca’s 5-Year Lynparza Data in Ovarian Cancer and MoreAdvanced Melanoma, Advanced Squamous Carcinoma of the Anal Canal (SCAC), Biomarkers, Blockbusters, Clinical Data, Clinical Trials, Epstein-Barr Virus, European Society for Medical Oncology (ESMO), Lung Cancer, Ovarian Cancer, PD-1/PD-L1 inhibitors, Platinum-Based Chemotherapy, R&D, Therapeutics
AstraZeneca and Merck announced positive five-year follow-up data from the Phase III SOLO-1 trial which demonstrated a long-term progression-free survival benefit of Lynparza as a first-line maintenance treatment in patients with newly diagnosed, advanced BRCA-mutated ovarian cancer who were in complete or partial response to platinum-based chemotherapy.
Roche received authorization from the U.S. Food and Drug Administration for the company’s cobas 6800/8800 diagnostic tests for transplant patients.
Some analysts have picked “winners and losers” from the 2018 J.P. Morgan Healthcare Conference. CNBC’s Jim Cramer made his picks related to stock performance.